[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2018000395A - Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso. - Google Patents

Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.

Info

Publication number
MX2018000395A
MX2018000395A MX2018000395A MX2018000395A MX2018000395A MX 2018000395 A MX2018000395 A MX 2018000395A MX 2018000395 A MX2018000395 A MX 2018000395A MX 2018000395 A MX2018000395 A MX 2018000395A MX 2018000395 A MX2018000395 A MX 2018000395A
Authority
MX
Mexico
Prior art keywords
proteins
methods
compositions containing
immunizing compositions
containing klebsiella
Prior art date
Application number
MX2018000395A
Other languages
English (en)
Inventor
T Burkhardt Douglas
Emery Daryll
STRAUB Darren
Original Assignee
Epitopix Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epitopix Llc filed Critical Epitopix Llc
Publication of MX2018000395A publication Critical patent/MX2018000395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/26—Klebsiella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente, se proveen proteínas aisladas que se pueden aislar de Klebsiella spp. También se proveen composiciones que incluyen una o más de las proteínas, así como métodos para producirlas y métodos para utilizarlas.
MX2018000395A 2015-07-10 2016-07-08 Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso. MX2018000395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190947P 2015-07-10 2015-07-10
PCT/US2016/041614 WO2017011340A2 (en) 2015-07-10 2016-07-08 Proteins and immunizing compositions containing klebsiella proteins and methods of use

Publications (1)

Publication Number Publication Date
MX2018000395A true MX2018000395A (es) 2018-05-23

Family

ID=56555778

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000395A MX2018000395A (es) 2015-07-10 2016-07-08 Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.

Country Status (7)

Country Link
US (3) US11000582B2 (es)
EP (1) EP3319628A2 (es)
JP (2) JP7222711B2 (es)
CN (1) CN107921114A (es)
CA (1) CA2991907A1 (es)
MX (1) MX2018000395A (es)
WO (1) WO2017011340A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03006038A (es) * 2001-01-03 2005-02-14 Willmar Poultry Co Inc Composiciones inmunizantes y metodos de uso.
JP7222711B2 (ja) * 2015-07-10 2023-02-15 エピトピックス， エルエルシー タンパク質及びｋｌｅｂｓｉｅｌｌａタンパク質を含有する免疫化組成物ならびにその使用方法
US10166280B2 (en) 2016-06-08 2019-01-01 Epitopix, Llc Polypeptides and immunizing compositions containing Bacillus polypeptides and methods of use
EP3579864B1 (en) * 2017-02-10 2023-04-12 Epitopix, LLC Proteins and immunizing compositions containing pasteurella proteins and methods of use
MX2021012952A (es) * 2019-04-26 2022-01-04 Univ Cornell Vacuna klebsiella y metodos de uso.
CN111647057B (zh) * 2020-05-07 2022-09-13 西南医科大学附属中医医院 一种伤寒沙门菌疫苗重组蛋白及其编码基因和它们的应用
EP4422677A1 (en) * 2021-10-29 2024-09-04 Vaxxinova US, Inc. Methods and compositions for preventing infection
CN115975890A (zh) * 2023-02-02 2023-04-18 深圳元健生命科技有限公司 一种产气克雷伯氏菌及其应用
CN115798574B (zh) * 2023-02-06 2023-06-02 中国医学科学院北京协和医院 一种预测克雷伯氏菌属对美罗培南敏感性的系统及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2644346B1 (fr) 1989-03-20 1994-05-13 Rhone Merieux Vaccins contre les bacteries septicemiques, preparations d'antigenes de bacteries septicemiques, nouvelles bacteries et vecteurs pour la preparation de ces antigenes ou vaccins
AU1915995A (en) 1994-02-09 1995-08-29 Willmar Poultry Company, Inc. Active immunization using a siderophore receptor protein
US5538733A (en) 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
JP3143388B2 (ja) 1996-02-07 2001-03-07 積水化学工業株式会社 屋根パネルならびにその屋根パネルを用いた建物の屋根構造
US6610836B1 (en) * 1999-01-29 2003-08-26 Genome Therapeutics Corporation Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics
US6682754B2 (en) 1999-11-24 2004-01-27 Willmar Poultry Company, Inc. Ovo delivery of an immunogen containing implant
MXPA03006038A (es) * 2001-01-03 2005-02-14 Willmar Poultry Co Inc Composiciones inmunizantes y metodos de uso.
CA2539074C (en) * 2003-09-19 2017-11-07 Epitopix, Llc Campylobacter polypeptides and methods of use
ES2586125T3 (es) * 2005-02-14 2016-10-11 Epitopix, Llc Polipéptidos de Staphylococcus aureus y métodos de uso
WO2008135446A2 (en) 2007-05-02 2008-11-13 Intercell Ag Klebsiella antigens
MX339461B (es) 2009-03-23 2016-05-27 Epitopix Llc Polipeptidos y composiciones inmunizantes que contienen polipeptidos grampositivos y metodos de uso.
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
JP7222711B2 (ja) * 2015-07-10 2023-02-15 エピトピックス， エルエルシー タンパク質及びｋｌｅｂｓｉｅｌｌａタンパク質を含有する免疫化組成物ならびにその使用方法

Also Published As

Publication number Publication date
US20190070281A1 (en) 2019-03-07
US11000582B2 (en) 2021-05-11
CA2991907A1 (en) 2017-01-19
WO2017011340A2 (en) 2017-01-19
US11872273B2 (en) 2024-01-16
WO2017011340A3 (en) 2017-04-13
JP2021063084A (ja) 2021-04-22
JP2018527405A (ja) 2018-09-20
US20240216494A1 (en) 2024-07-04
US20210330776A1 (en) 2021-10-28
JP7222711B2 (ja) 2023-02-15
EP3319628A2 (en) 2018-05-16
CN107921114A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2019007021A (es) Anticuerpos il-11ra.
MX2019007020A (es) Anticuerpos il-11.
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
PH12017500861A1 (en) Anti-interleukin-33 antibodies and uses thereof
MY191581A (en) Anti-pd-1 antibodies
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
SG10201803042PA (en) Anti-tim-3 antibodies
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
MY192927A (en) Fused bicyclic compounds for the treatment of disease
MX2017016169A (es) Anticuerpos anti-her2 y metodos de uso.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2022000053A (es) Moduladores de interaccion de sestrina-gator2 y sus usos.
MX2016015162A (es) Anticuerpos anti - gpc3 e inmunoconjugados.
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
MX2020003760A (es) Formulaciones de niraparib.
IL280809B (en) New preparations, their use and methods of their creation
MX2020012893A (es) Formulaciones de proteinas.
MX2017008390A (es) Uretanos funcionalizados con alcoxisilano y funcionalizados con alofanato.
SG11201609677WA (en) Method for reducing the chlorine content of organomonophosphites using dimethylaminobutane, triethylamine or triethanolamine
MX2017000527A (es) Formulaciones de anticuerpos cristalinos.
MX2021006003A (es) Formulaciones de anticuerpos cristalinos.
MX2017010883A (es) Composicion para el tratamiento de la infertilidad.
MX370897B (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades,.
GB201804163D0 (en) Uses, compositions and methods